NEW YORK – Using single-cell sequencing data, researchers from the University of Texas MD Anderson Cancer Center have begun to explore the clonal diversity and determine the evolution of acute myeloid leukemia.
By better understanding the heterogeneity of cancer cells, researchers can gain insight into both how cancer develops as well as which targeted treatments might be best used to treat it. To that end, researchers led by MD Anderson's Koichi Takahashi conducted single-cell sequencing of samples from more than 100 AML patients.